Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder

October 26, 2021 updated by: Roger McIntyre, Brain and Cognition Discovery Foundation

Cognitive dysfunction is a highly persistent, pervasive and progressive abnormality in young adults (i.e., 18-65 years) with MDD. It has also been shown that among adults with MDD who are gainfully employed, measures of cognition are a greater determinant of overall workplace performance than is total depression symptom severity. Several lines of evidence indicate that cognitive deficits that persist between episodes of depression are critical determinants of functional recovery in the workplace. The functional implications associated with cognitive impairment provide the impetus for systematic evaluation, measurement and assessment of the domains of cognition expected to be impaired in this patient population.

To date, no measurement tool has been sufficiently validated and/or determined to be sensitive to the cognitive deficits in younger adults with MDD. Major limitations of available comprehensive psychometric tools include relative lack of availability, cost, lack of access to most healthcare providers, and above all else, the lengthy time to administer. Moreover, the need for a psychometrist to interpret the results adds to the complexity and the costliness of such an endeavor.

It is imperative that any tool recommended for clinical utility be aligned with the busy nature of a high-volume clinical practice. The ideal gold standard tool for assessing the presence of cognitive dysfunction in MDD in the clinical environment should include, but not be limited to, features such as good conceptual coverage of cognitive domains affected in MDD, good sensitivity and reliability, and it should be relatively uninfluenced by culture effects and practice effects. The tool would also need to be brief, easy to administer and interpret, and complement busy clinical practice.

This study is designed to validate a brief user-friendly tool capable of detecting deficit in cognitive performance among adults with MDD. Data will be gathered with the aim to determine whether the proposed tool identifies cognitive deficits in adults with MDD and differentiates the clinical MDD population from healthy controls.

It is anticipated that the THINC-it tool will be free of charge and downloadable from the THINC-it website for use in the primary care and specialty setting. The THINC-it tool will be accessible via computers/tablets, will take 20 minutes to self-administer in a clinical setting, and the performance results will be immediately available.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, L5C 4E7
        • CRTCE/KJK Healthplex

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients will be enrolled at a single site, located in Toronto, Ontario, Canada. The total planned number of participants is:

  • 100 individuals with DSM-5-defined MDD, aged 18-65
  • 100 healthy controls matched on age, sex and years of education An equal allocation of subjects with MDD between the ages of 18-44 and 45-65 will be enrolled.

Healthy controls will be consecutively recruited via media announcements.

Description

MDD Population:

Inclusion Criteria:

  • That participant is able and willing to provide informed consent.
  • The participant is male or female between the ages of 18-65.
  • The participant has received a diagnosis of a major depressive disorder (MDE) as per DSM-5 criteria.
  • Current MDE is confirmed by the MINI for DSM-IV-TR.
  • The participant is an outpatient at a psychiatric setting.
  • The participant has a MADRS score equal to or greater than 22.
  • The reported duration of current depressive episode is at least 3 months.
  • The participant has been receiving a stable antidepressant dose for a minimum of 2 weeks prior to the study visit.
  • At least one prior episode by history of depression validated by previous treatment (e.g. guidelines-informed pharmacotherapy and/or manual-based psychotherapy).
  • Health Canada-approved antidepressant; add-on agents commensurate with Canadian (i.e. CANMAT) and American treatment-guidelines for MDD will be permitted.
  • Enrollment in manual-based and/or supportive psychotherapy will be permitted.

Exclusion Criteria:

  • Current alcohol and/or substance use disorder.
  • Presence of comorbid psychiatric disorder other than MDD that is a focus of clinical concern as confirmed by the MINI for DSM-IV-TR.
  • Medications approved for and/or employed off label for cognitive dysfunction (e.g. psychostimulants).
  • Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
  • Use of benzodiazepines within 12 hours of THINC-it tool administration.
  • Consumption of alcohol within 8 hours of THINC-it tool administration.
  • The patient has physical, cognitive, or language impairment of some severity as to adversely affect the validity of the data derived from neuropsychological tests.
  • The patient is diagnosed with a reading disability or dyslexia.
  • The patient cannot have a clinically significant learning disorder by history.
  • The patient has received electroconvulsive therapy (ECT) in the last 6 months.
  • The patient has a history of moderate or severe head trauma (e.g. loss of consciousness for over 1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system.

Healthy Controls:

Inclusion Criteria:

  • No current or past history of mental disorder as evidence by MINI or DSM-IV-TR.
  • No first-degree relative with an established diagnosis by a healthcare provider of a mood or psychiatric disorder.
  • No unstable medical disorders.

Exclusion Criteria:

  • Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
  • Consumption of alcohol within 8 hours of THINC-it tool administration.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Major Depressive Disorder Population
100 Individuals with DSM-5-defined MDD, aged 18-65

Digitalized cognitive test application administering the following cognitive test components:

  • Digit Symbol Substitution Test (DSST)
  • Choice Reaction Time (CRT)
  • One-back working memory tool
  • Trail Making Test B (TMT-B)
  • Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)

Pencil-and-paper versions of the following cognitive tests:

  • Digit Symbol Substitution Test (DSST)
  • Trail Making Test B (TMT-B)
  • Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
  • Variant of Choice Reaction Time (CRT)
  • Variant of the One-back working memory tool
Healthy Control Population
100 healthy controls matched on age, sex and years of education

Digitalized cognitive test application administering the following cognitive test components:

  • Digit Symbol Substitution Test (DSST)
  • Choice Reaction Time (CRT)
  • One-back working memory tool
  • Trail Making Test B (TMT-B)
  • Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)

Pencil-and-paper versions of the following cognitive tests:

  • Digit Symbol Substitution Test (DSST)
  • Trail Making Test B (TMT-B)
  • Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
  • Variant of Choice Reaction Time (CRT)
  • Variant of the One-back working memory tool

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite THINC-it Tool Score
Time Frame: up to1 week
The composite THINC-it tool score is the integrated total score of results from performance on five sub-component cognitive tests of the THINC-it tool.
up to1 week
Digit Symbol Substitution Test (DSST) - THINC-it tool version
Time Frame: Up to 1 week
Up to 1 week
Choice Reaction Time (CRT) - THINC-it tool version
Time Frame: Up to 1 week
Up to 1 week
One-back working memory test - THINC-it tool version
Time Frame: Up to 1 week
Up to 1 week
Trail Making Test B - THINC-it tool version
Time Frame: Up to 1 week
Up to 1 week
Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - THINC-it tool version
Time Frame: Up to 1 week
Up to 1 week
Digit Symbol Substitution Test (DSST) - Pencil-and-paper version
Time Frame: Up to 1 week
Up to 1 week
Choice Reaction Time (CRT) - Pencil-and-paper version
Time Frame: Up to 1 week
Up to 1 week
One-back working memory test - Pencil-and-paper version
Time Frame: Up to 1 week
Up to 1 week
Trail Making Test B - Pencil-and-paper version
Time Frame: Up to 1 week
Up to 1 week
Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - Pencil-and paper version
Time Frame: Up to 1 week
Up to 1 week

Secondary Outcome Measures

Outcome Measure
Time Frame
Endicott Workplace Productivity Scale (EWPS)
Time Frame: Up to 1 week
Up to 1 week
Sheehan Disability Scale (SDS)
Time Frame: Up to 1 week
Up to 1 week
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Up to 1 week
Up to 1 week
Clinical Global Impression (CGI)
Time Frame: Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame: Up to 1 week
Up to 1 week
Generalized Anxiety Disorder 7-Item (GAD-7)
Time Frame: Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
WHO-5 Well-being Index (WHO-5)
Time Frame: Up to 1 week
Up to 1 week
Visual Analog Scale (VAS)
Time Frame: Up to 1 week
Up to 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roger McIntyre, Brain and Cognition Discovery Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

July 1, 2016

Study Registration Dates

First Submitted

July 22, 2015

First Submitted That Met QC Criteria

July 23, 2015

First Posted (Estimate)

July 27, 2015

Study Record Updates

Last Update Posted (Actual)

October 27, 2021

Last Update Submitted That Met QC Criteria

October 26, 2021

Last Verified

October 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on THINC-it Tool

Subscribe